INmune Bio (NASDAQ: INMB)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-02 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.500 | -0.380 | 0.1200 | ||||
REV | 16.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of INmune Bio (NASDAQ: INMB) through any online brokerage.
Other companies in INmune Bio’s space includes: Impel Pharmaceuticals (NASDAQ:IMPL), 89bio (NASDAQ:ETNB), Celcuity (NASDAQ:CELC), Viracta Therapeutics (NASDAQ:VIRX) and La Jolla Pharmaceutical (NASDAQ:LJPC).
The latest price target for INmune Bio (NASDAQ: INMB) was reported by BTIG on Tuesday, May 24, 2022. The analyst firm set a price target for 14.00 expecting INMB to rise to within 12 months (a possible 54.19% upside). 3 analyst firms have reported ratings in the last year.
The stock price for INmune Bio (NASDAQ: INMB) is $9.08 last updated August 17, 2022, 8:00 PM UTC.
There are no upcoming dividends for INmune Bio.
INmune Bio’s Q3 earnings are confirmed for Wednesday, November 2, 2022.
There is no upcoming split for INmune Bio.
INmune Bio is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.